Source comparison
Cerebrolysin BPC-157 Protocol TBI Research: Evidence vs Clinical Translation
Cerebrolysin Neurotrophic factor mimicry (BDNF, NGF pathway activation) 0–72 hours post-injury (acute neuroprotection) 2.5mL/kg IV daily × 10–21 days 22–28% lesion volume reduction; mNSS improvement 0.42–0.68 effect size Phase II/III trials completed in stroke
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Neurotrophic factor mimicry (BDNF, NGF pathway activation)
- 0–72 hours post-injury (acute neuroprotection)
- 2.5mL/kg IV daily × 10–21 days
- 22–28% lesion volume reduction; mNSS improvement 0.42–0.68 effect size
- Phase II/III trials completed in stroke; limited TBI-specific trials
- BPC-157
- Angiogenesis, anti-inflammatory (VEGFR2, eNOS modulation)
- 3–21 days post-injury (subacute repair)
- 10–500μg/kg SC/IP daily × 14–21 days
- 31% edema reduction; 42% microvascular density increase
- Preclinical only; no registered human TBI trials as of 2026
- Combined Sequential Protocol
- Temporal coordination of neuroprotection + vascular repair
- Cerebrolysin days 1–10; BPC-157 days 7–21
- As above, overlapping days 7–10
- 38% cognitive improvement; 29% tissue loss reduction vs monotherapy
- Experimental; no standardized clinical protocol exists